Goff Brian 4

What Happened

• Brian Goff, CEO of Agios Pharmaceuticals (AGIO), had 39,000 performance stock units (PSUs) converted/exercised into 39,000 restricted stock units (RSUs) on June 18, 2026. The reported price is $0.00, so there was no cash payment and no immediate taxable sale or proceeds.

Key Details

• Transaction date: June 18, 2026; Form 4 filed: June 23, 2026 (filing appears one business day late vs. the usual 2-business-day rule).
• Reported transactions: M (exercise/conversion) — 39,000 derivative units @ $0.00 (disposed); A (award) — 39,000 units @ $0.00 (acquired).
• Shares owned after the transaction: not specified in the filing.
• Footnotes: F1–F3 state that PSUs are contingent rights to one share each; these PSUs were granted 3/1/2025 and vested as to the specified research milestone on 6/18/2026 (F2). The shares related to that milestone will vest on 12/31/2027, subject to continued service. F3 defines RSUs as contingent rights to one share each.

Context

• This transaction reflects a conversion/recognition of a performance award (milestone achieved) rather than a market buy or sell. No shares were reported sold for cash; the action creates an award/claim on future shares that remain subject to a service-based vesting date (12/31/2027).
• Because the filing date is after the 2-business-day reporting window, investors may note the late filing but should focus on the nature of the event: a milestone-triggered award conversion, not an open-market trade indicating immediate insider sentiment.